Capricor Therapeutics CAPR
NASDAQ CAPR
$8.95 +0.01 (+0.11%)
At close: Oct 2, 2026 · 4:00 PM EDT

Capricor Therapeutics (CAPR) Gains from Sales and Divestitures (2011 - 2025)

Updated

Capricor Therapeutics (CAPR) recorded Gains from Sales and Divestitures of -$157,519 in FY2025, compared with -$112,805 in FY2024.

Analysis

Capricor Therapeutics (CAPR) Gains from Sales and Divestitures (2011 - 2025) Analysis & Trends

Starting with FY2011, Capricor Therapeutics' Gains from Sales and Divestitures history includes 7 years.

  • The FY2025 figure is the lowest annual Gains from Sales and Divestitures in data going back to FY2011.
  • Per Business Quant data, CAPR's Gains from Sales and Divestitures was -$112,805 in FY2024, -$6,041 in FY2023, -$34,266 in FY2022 and -$7,905 in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Capricor Therapeutics 520.08 Mn 520.08 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 -6,846.00
Mar 31, 2025 -150,673.00
Dec 31, 2023 -653.00
Sep 30, 2023 -5,388.00
Dec 31, 2022 -34,266.00
Jun 30, 2019 -2,720.00
Dec 31, 2013 1,307.00
Jun 30, 2013 -1,307.00
Dec 31, 2011 -1,501.00
API Access

Capricor Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=CAPR&period=max&api_key=YOUR_API_KEY